Takeda Pharmaceutical (4502.T): New data on zasocitinib slightly positive; awaiting NDA and results for additional indications

Research evidence excerpt

Takeda Pharmaceutical (4502.T): New data on zasocitinib slightly positive; awaiting NDA and results for additional indications

Takeda Pharmaceutical (4502.T)

17 July 2026 Citi Research

Citigroup Global Markets Inc. or its affiliates currently has, or had within the past 12 months, the following as investment

banking client(s): Takeda Pharmaceutical.

Citigroup Global Markets Inc. or its affiliates currently has, or had within the past 12 months, the following as clients, and the

services provided were non-investment-banking, securities-related: Takeda Pharmaceutical.

services provided were non-investment-banking, non-securities-related: Takeda Pharmaceutical.

Citigroup Global Markets Inc. or an affiliate received compensation in the past 12 months from Takeda Pharmaceutical.

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to Takeda Pharmaceutical. (For

an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest

which can be found at www.citiVelocity.com.)

Analysts’ compensation is determined by Citi Research management and Citigroup’s senior management and is based upon

activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates (the “Firm”).

Compensation is not linked to specific transactions or recommendations. Like all Firm employees, analysts receive

compensation that is impacted by overall Firm profitability which includes investment banking, sales and trading, and

principal trading revenues. One factor in equity research analyst compensation is arranging corporate access events between

institutional clients and the management teams of covered companies.